#### REVIEW



# Does previous transurethral resection of the prostate negatively influence subsequent robotic-assisted radical prostatectomy in men diagnosed with prostate cancer? A systematic review and meta-analysis

Li Gu<sup>2</sup> · Yijian Li<sup>1</sup> · Xurui Li<sup>1</sup> · Wentao Liu<sup>1</sup>

Received: 14 February 2023 / Accepted: 26 March 2023 / Published online: 5 April 2023 © The Author(s), under exclusive licence to Springer-Verlag London Ltd., part of Springer Nature 2023

#### Abstract

It is not uncommon to incidentally discover prostate cancer during the transurethral resection of the prostate (TURP) for the treatment of benign prostatic hyperplasia and necessitate a subsequent robotic-assisted radical prostatectomy (RARP). The study aims to evaluate whether TURP have negative influence on subsequent RARP. Through a literature search using MEDLINE, EMBASE and the Cochrane Library, 10 studies with 683 patients who underwent RARP after previous TURP and 4039 patients who underwent RARP only were identified for the purposes of the meta-analysis. Compared to standard RARP, RARP after TURP was related to longer operative time (WMD: 29.1 min, 95% CI: 13.3–44.8, P < 0.001), more blood loss (WMD: 49.3 ml, 95% CI: 8.8–89.7, P=0.02), longer time to catheter removal (WMD: 0.93 days, 95% CI: 0.41–1.44, P < 0.001), higher rates of overall (RR: 1.45, 95% CI: 1.08–1.95, P=0.01) and major complications (RR: 3.67, 95% CI: 1.63–8.24, P = 0.002), frequently demand for bladder neck reconstruction (RR: 5.46, 95% CI: 3.15–9.47, P < 0.001) and lower succeed in nerve sparing (RR: 0.73, 95% CI: 0.62-0.87, P < 0.001). In terms of quality of life, there are worse recovery of urinary continence (RR of incontinence rate: RR: 1.24, 95% CI: 1.02–1.52, P=0.03) and potency (RR: 0.8, 95% CI: 0.73–0.89, P < 0.001) at 1 year in RARP with previous TURP. In addition, the RARP with previous TURP had greater percentage positive margins (RR: 1.24, 95% CI: 1.02–1.52, P=0.03), while there is no difference in length of stay and biochemical recurrence rate at 1 year. RARP is feasible but challenging after TURP. It significantly increases the difficulty of operation and compromises surgical, functional and oncological outcomes. It is important for urologists and patients to be aware of the negative impact of TURP on subsequent RARP and establish treatment strategies to lessen the adverse effects.

**Keywords** Prostate cancer  $\cdot$  Robotic-assisted radical prostatectomy  $\cdot$  Transurethral resection of the prostate  $\cdot$  Quality of life  $\cdot$  Prognosis  $\cdot$  Safety

## Introduction

Prostate cancer (PCa) is the most frequent cancer, and as the second leading cause of cancer-related mortality in men in western countries, is a global public health problem [1]. Radical prostatectomy is recommended as the standard

Wentao Liu xyeyylwt@csu.edu.cn treatment for localized prostate cancer. With the advances in robotic-assisted technique, robotic-assisted radical prostatectomy (RARP) has become the dominant prostatectomy approach [2].

Generally, prostate cancer is diagnosed by prostate biopsy on the basis of elevated prostate-specific antigen (PSA) or abnormal digital rectal examination. However, age is a risk factor for both benign prostatic hyperplasia (BPH) and prostate cancer, hence it is not uncommon for older men to be incidentally identified with prostate cancer during a transurethral resection of the prostate (TURP) performed to treat their BPH. This accounts for between 2 and 12% of all new cases of prostate cancer [3–5]. Patients incidentally discovered of prostate cancer during TURP are recommended to

<sup>&</sup>lt;sup>1</sup> Department of Urology, The Second Xiangya Hospital, Central South University, Changsha 410011, Hunan, China

<sup>&</sup>lt;sup>2</sup> Department of Gastroenterology, The Second Xiangya Hospital, Central South University, Changsha 410011, Hunan, China

receive a consecutive radical prostatectomy after 3 months. It is anticipated that periprostatic inflammation, fibrosis, and adhesion of the surgical planes caused by perforation of the prostatic capsule and extravasation of blood and irrigation fluid during TURP would make future RARP more challenging. As a consequence, several studies have been published to evaluate the impact of prior TURP on RARP, however, showed controversial findings [4, 6–9].

In order to benefit the men who underwent RARP with a history of TURP, the internal association between TURP and RARP is of paramount importance. Hence, we performed a meta-analysis of the available literature to evaluate the surgical, functional or oncological outcomes between RARP with or not previous TURP. Moreover, we hypothesized that RARP with previous TURP offers undesirable outcomes, therefore, a literature review would be made to find out some strategies to mitigate the adverse effect of TURP on RARP.

### **Methods**

#### Search strategy and study selection

Following the guidelines established by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA), a comprehensive review was conducted [10]. This study is registered at the INPLASY register (INPLASY202310062). For this purpose, we searched MEDLINE, EMBASE, and the Cochrane Library from 1998 to November 2022 that met our criteria for inclusion. The search terms were ("TURP" OR "transurethral resection" OR "enucleation") AND ("robotic OR "robot" OR "robot assisted") AND ("radical prostatectomy"). There were no linguistic constraints imposed. The references of retrieved articles were also searched for additional studies. The following requirements should be satisfied by the chosen studies: (1) randomized controlled trials, prospective or retrospective cohort study; (2) compared robot-assisted radical prostatectomy patients with previous TURP (TURP Group) to patients without TURP (no-TURP Group); (3) reported at least one surgical, functional or oncological outcomes of interest; (4) studies relied on a mixed surgical cohort (robotassisted, laparoscopic, open) were excluded; (5) letters to the editor, reviews, case-series and case reports were not considered, and (6) in the event when studies focusing on the same population, the more informative of the information was included.

#### Data extraction and quality assessment

Two authors meticulously and independently retrieved data from relevant research, which may include demographics, surgical results, functional, or oncological outcomes. Statistical techniques were used to determine standard deviations (SDs) for research that provided continuous data as means and ranges [11]. The quality of individual included studies was assessed based on the Downs and Black tool [12] by two authors independently. All disagreements were resolved through discussions with another author. When necessary information was missing from the available studies, we contacted the study's corresponding author for more details.

#### **Outcomes of interest**

The surgical outcomes of interest were operative time, estimated blood loss (EBL), time to catheter removal, length of hospital stay (LOS), overall complications, major complications, bladder neck construction and neurovascular bundle (NVB) sparing rate. The functional outcomes included urinary incontinence and potency at 1 year. Either incontinence or potency reported within 1 year or at the last follow-up were not extracted for analysis. The oncological outcomes were positive margin and biochemical recurrence rates (BCR).


#### **Statistical analysis**


Comparisons of continuous and dichotomous variables were performed using weighted mean difference (WMD) and risk ratio (RR), respectively, along with 95% confidence interval (95% CI). A P value < 0.05 was considered statistically significant. The presence of heterogeneity between studies were calculated by the  $\chi^2$  based Q test and  $I^2$ . An  $I^2$  value > 50% accompanied with P value < 0.05 was considered to indicate substantial heterogeneity, in which case, the pooled effect was calculated by a random-effects model (the DerSimonian and Laird method). Otherwise, the fixed effects model (Mantel-Haenszel method) was used for the meta-analysis [13]. For pooled outcomes with significant heterogeneity, sensitivity analyses were performed to explore the potential effect of heterogeneity by eliminating studies that did not use propensity scoring matching. Begg's funnel plot and Egger's test were used to evaluate the possibility of publication bias. All the statistical analyses were performed using Review Manager Version 5.4 (The Cochrane Collaboration, Oxford, London, United Kingdom) and STATA software (version 15.0; Stata Corporation, College Station, TX).

## Results

#### Study selection and characteristics of studies

Figure 1 is a flowchart depicting the processes used to choose relevant literature. Our search of the literature yielded a total





of 203 articles. After excluding the duplicates and articles not met the inclusion criteria based on the title, abstract scan and subsequent full-text scan, 10 articles with 683 and 4039 patients in TURP and no-TURP group were included in our meta-analysis [3–9, 14–16]. The characteristics and quality assessment of included studies are shown in Table 1. Both ten articles were retrospective cohort design and 3b in level of evidence. Among them, seven articles performed a propensity scoring matching (PSM) [6–9, 14–16], in which age, prostate-specific antigen (PSA) and Gleason score were the most frequent matching factors. According to the quality ratings, the majority of the articles were considered to be of a moderate standard (mean 17, SD 1.49).

#### Surgical outcomes

Results are summarized in Table 2 and Fig. 2. Compared to the No-TURP group, the operative time (seven articles extracted) of TURP Group is significant longer (WMD: 29.1 min, 95% CI: 13.3–44.8, P < 0.001;  $I^2 = 81\%$ , P < 0.001). In terms of the EBL (eight articles extracted), the TURP Group offered unfavorable outcomes than the No-TURP group (WMD: 49.3 ml, 95% CI: 8.8-89.7,  $P = 0.02; I^2 = 93\%, P < 0.001$ ). Patients in TURP Group demonstrated longer time to catheter removal (WMD: 0.93 days, 95% CI: 0.41–1.44, P < 0.001;  $I^2 = 39\%$ , P = 0.16) and similar LOS (WMD: 0.03 days, 95% CI: -0.31-0.37, P=0.85;  $I^2=0\%$ , P=0.71), as reported in five and three article, respectively. The overall (RR: 1.45, 95% CI: 1.08–1.95, P = 0.01;  $I^2 = 27\%$ , P = 0.24) and major complication rates (RR: 3.67, 95% CI: 1.63-8.24, P = 0.002;  $I^2 = 19\%$ , P = 0.3) was significantly higher in TURP group than no-TURP group. Regarding to rates of bladder neck reconstruction, 64.7% patients in TURP group received bladder neck reconstruction, which is much higher than that in no-TURP group (9.9%, RR: 5.46, 95%

Table 1 Characteristic and quality of retrieved studies

References	Year	Patient number		Design, LOE	PSM	Matching factors	Quality score	TURP technique
		TURP	no-TURP					
Hampton [14]	2008	51	102	R,3b	Yes	1, 7	16	Standard
Abedali [15]	2010	27	27	R,3b	Yes	1,3, 4	17	HoLEP
Gupta [3]	2011	18	132	R,3b	No	No	15	NR
Zugor [9]	2012	80	80	R,3b	Yes	1,2,3,4,5,6	19	NR
Hung [4]	2014	16	184	R,3b	No	No	16	NR
Gellhaus [8]	2015	11	22	R,3b	Yes	3,4	17	HoLEP
Su [5]	2015	49	2644	R,3b	No	No	15	NR
Tugcu [7]	2015	25	36	R,3b	Yes	1, 2, 3, 4,5,6	18	Mixed*
Bannurah [16]	2021	368	736	R,3b	Yes	1,3,4,5, 6, 7	19	Mixed**
Garg [6]	2022	38	76	R,3b	Yes	1, 3, 4	18	NR

*PSM* Propensity scoring matching. *LOE* level of evidence. *R* retrospective. 1 = age, 2 = body mass index (BMI), 3 = prostate-specific antigen (PSA), 4 = Gleason score, 5 = prostate volume, 6 = pathological staging, 7 = nerve-sparing status. *NR* none reported

\*Standard resection and open surgery

\*\*Standard resection and HoLEP

 Table 2
 Overall meta-analysis of and outcomes of interest

Outcomes of interest	No. of studies	No of par	tients	WMD/RR (95% CI)	P value	Heterogeneity	
		TURP No-TURP				I <sup>2</sup>	P value
Surgical outcomes							
Operating time, min	7	565	1161	29.1 (13.3, 44.8)	0.001	81%	0.001
EBL, ml	8	607	3901	49.3 (8.8, 89.7)	0.02	93%	0.001
Time to catheter removal, day	5	172	389	0.93 (0.41, 1.44)	0.001	39%	0.16
LOS, day	3	103	2904	0.03 (- 0.31, 0.37)	0.85	0%	0.71
Overall complications	6	554	1139	1.45 (1.08,1.95)	0.01	27%	0.24
Major complications	4	159	376	3.67 (1.63, 8.24)	0.002	19%	0.3
Bladder neck reconstruction	7	215	557	5.46 (3.15, 9.47)	0.001	53%	0.05
NVB sparing	5	159	349	0.73 (0.62, 0.87)	0.001	49%	0.1
Functional outcomes							
Incontinence at 1 year	6	535	1197	1.54 (1.19, 2)	0.001	21%	0.28
Potency at 1 year	5	496	959	0.8 (0.73, 0.89)	0.001	16%	0.31
Oncologic outcomes							
Positive margin	10	683	4039	1.24 (1.02, 1.52)	0.03	0%	0.79
BCR at 1 year	3	392	1005	1.41 (0.87, 2.29)	0.16	36%	0.21

Statistically significant values are highlighted in bold

WMD/RR weighted mean difference/risk ratio, EBL estimated blood loss, LOS length of hospital stay, NVB neurovascular bundle, BCR biochemical recurrence-free rates

CI: 3.15–9.47, P < 0.001;  $I^2 = 53\%$ , P = 0.05). Six articles reported NVB sparing rate, among which one article [16] propensity scoring matched with NVB sparing, thus five articles were extracted for pooled analysis, and the results showed less patients in TURP group successfully received NVB sparing than that in no-TURP group (RR: 0.73, 95% CI: 0.62–0.87, P < 0.001;  $I^2 = 49\%$ , P = 0.1). Since the heterogeneity exist in pooled outcomes of operative time, EBL and bladder neck reconstruction, the sensitivity analyses were performed by excluding non-PSM studies. Both the operative time (WMD: 30.3 min, 95% CI: 13.6–47.1, P < 0.001) and bladder neck reconstruction rate (RR: 6.38, 95% CI: 2.6–15.6, P < 0.001) exhibited permanent significant differences. Though the TURP group had greater EBL (WMD: 44.2 ml, 95% CI: -5.9-94.4, P=0.08), the difference was not statistically significant (Supplemental Fig. 1). Fig. 2 Forest plot of operative time (A), estimated blood loss (**B**), time to catheter removal (C), overall complications (D), major complications (E), bladder neck reconstruction (F), and nerve sparing (G)

Study or Subgroup 2010 Abedali		URP		no-TURA			Mean Differen		Mean Difference
	Mean		fotal Mea			Weight	IV, Random, 9		IV, Random, 95% Cl
2012 Zugor	193.5 189	43.4	27 164.		27	15.3%	29.30 [8.48, 5 40.00 [16.47, 6		
2012 Lugor 2014 Hung		104.4	16 17		184	6.4%	12.60 [-39.00, 6		
2015 Gellhaus	216.6	18	11 164.	6 38	22	15.9%	52.00 [32.89, 7	71.11]	
2015 Tugcu	238.6	67.6	25 203		36	11.3%	35.00 [3.31, 6	66.69]	
2021 Bannurah 2022 Garg	150 203.7	6.8 44.7	368 14			20.8%	10.00 [9.11, 1 23.80 [5.06, 4		
	200.7	44.7		5 54.5			20.00 [0.00, 4	12.54	
Total (95% CI) Heterogeneity: Tau <sup>2</sup> :	= 311.36 (	Chi <sup>z</sup> = 32	565 2.34. df = 6	(P < 0.0	1161 ·		29.11 [13.34, 4		· · · · ·
Test for overall effect									100 -50 0 50 10 Favours TURP Favours no-TURP
B. blood loss	TUP	æ	no	-TURP			Mean Differenc		Mean Difference
Study or Subgroup 2010 Abedali	Mean 160	SD Tot 93	tal Mean 27 130	SD 62		leight 3.1%	IV, Random, 99 30.00 [-12.16, 7		IV. Random, 95% Cl
2011Gupta			18 358.3	35.3		0.1% 1	35.80 [62.28, 20		
2012 Zugor			80 144	196.3		2.9%	21.00 [-22.96, 6		
2014 Hung 2015 Gellhaus			16 183 11 130.7	18 65.5		9.6% -: 0.4%	38.00 [-116.93, 4 78.40 [7.98, 14		
2015Su			49 116.6			4.3%	70.40 [43.73, 9		
2021 Bannurah	200 3	4.1 3	68 200	31.8	736 1	5.2%	0.00 [-4.17,	4.17]	
2022 Garg	330 7		38 230	57.2			00.00 [74.24, 12		
Total (95% CI) Heterogeneity: Tau² = :	2798.77; C	60 hi² = 10			3901 10 0001); I <sup>2</sup> :		49.30 [8.83, 8	H	200 -100 0 100 200
Test for overall effect: 2								-	Favours TURP Favours no-TURP
C. time to cath							Maan Differen		Maan Differense
Study or Subgroup		URP SD 1	fotal Mea	no-TUR in SD	P Total	Weight	Mean Differen IV, Fixed, 95%		Mean Difference IV, Fixed, 95% Cl
2010 Abedali	8.3	2	27 7	.8 1.9	27	24.2%	0.50 [-0.54, 1	.54]	
2012 Zugor	6.8	4.3		.2 0.2		29.5%	1.60 [0.66, 2	.54]	
2014 Hung	9.31	2.82		9 2.57		12.8%			
2015 Gellhaus 2022 Garg	7.7 16	1.6		4 1.3		22.1% 11.4%			
	10	4.2							
Total (95% CI) Heterogeneity: Chi <sup>2</sup>	= 6.51, df	= 4 (P =	172 0.16); I <sup>2</sup> =	39%	389	100.0%	0.93 [0.41, 1.	.44] ⊢ -4	-2 0 2
Test for overall effec								-4	-2 0 2 Favours TURP Favours no-TURP
D. length of h		stay URP		no-TUR	D		Mean Differen	ice	Mean Difference
Study or Subgroup	Mean	SD 1	fotal Mea	n SD	Total	Weight	IV, Fixed, 95%	% CI	IV, Fixed, 95% Cl
2014 Hung 2015Su	4.19	2	16 3.7 49 4.5			10.9%	0.42 [-0.61, 1		
2015Su 2022 Garg	4.56	1.33	49 4.5 38 5			82.7% 6.5%	0.00 [-0.37, 0 -0.20 [-1.54, 1		
Total (95% CI)			103			100.0%			<b>—</b>
Heterogeneity: Chi <sup>2</sup>	= 0.69. df	= 2 (P =		0%	2904	100.0%	0.03 [-0.31, 0.	H	
Test for overall effec								-2	-1 Ó 1 Favours TURP Favours no-TURP
E. overall com	plicatio	ons							
	TU	RP	no-TU				sk Ratio		Risk Ratio
Study or Subgroup		s Tota			Weight		Fixed, 95% CI		M-H, Fixed, 95% Cl
2010 Abedali	1			27	0.8%		0 [0.25, 99.51]		
2012 Zugor	20			80	12.7%		50 [1.17, 5.34]		
2014 Hung	4	4 16	6 20	184	5.1%	2.2			
							80 [0.89, 5.91]		
2015 Tugcu	10			36	9.1%	2.0	06 [0.91, 4.67]		
2015 Tugcu 2021 Bannurah	10 31	1 368	54	736	9.1% 57.4%	5 2.0 5 1.1	06 [0.91, 4.67] 5 [0.75, 1.75]		
2015 Tugcu 2021 Bannurah 2022 Garg	10	1 368 6 38	3 54 3 14	736 76	9.1% 57.4% 14.9%	5 2.0 5 1.1 5 0.8	06 [0.91, 4.67] 5 [0.75, 1.75] 86 [0.36, 2.05]		
2015 Tugcu 2021 Bannurah 2022 Garg Total (95% CI)	10 31 6	1 368 6 38 554	3 54 3 14	736	9.1% 57.4%	5 2.0 5 1.1 5 0.8	06 [0.91, 4.67] 5 [0.75, 1.75]		
2015 Tugcu 2021 Bannurah 2022 Garg Total (95% CI) Total events	10 31 6 73	1 368 6 38 554	3 54 3 14 4 103	736 76 1139	9.1% 57.4% 14.9%	5 2.0 5 1.1 5 0.8	06 [0.91, 4.67] 5 [0.75, 1.75] 86 [0.36, 2.05]	L	
2015 Tugcu 2021 Bannurah 2022 Garg Total (95% CI) Total events Heterogeneity: Chi <sup>2</sup> Test for overall effec	10 31 6 = 6.81, df ct: Z = 2.48	1 368 554 3 = 5 (P = 3 (P = 0	3 54 3 14 103 = 0.24);   <sup>2</sup>	736 76 1139	9.1% 57.4% 14.9%	5 2.0 5 1.1 5 0.8	06 [0.91, 4.67] 5 [0.75, 1.75] 86 [0.36, 2.05]	0.1	0.2 0.5 1 2 5 10 Favours TURP Favours no-TURP
2015 Tugou 2021 Bannurah 2022 Garg Total (95% CI) Total events Heterogeneity: Chi <sup>2</sup> Test for overall effec	10 31 6 = 6.81, df ct Z = 2.48 olicatio	1 368 554 3 = 5 (P = 0 3 (P = 0	3 54 3 14 103 = 0.24); I <sup>2</sup> .01)	736 76 1139 = 27%	9.1% 57.4% 14.9%	5 2.0 5 1.1 5 0.8 6 <b>1.4</b>	06 [0.91, 4.67] 15 [0.75, 1.75] 36 [0.36, 2.05] 5 <b>[1.08, 1.95]</b>	0.1	Favours TURP Favours no-TURP
2015 Tugču 2021 Bannurah 2022 Garg Total (95% CI) Total events Heterogeneity: Chi <sup>2</sup> Test for overall effec F. marjor comp Study or Subgroup	10 31 6 = 6.81, df ct: Z = 2.48	1 368 554 3 = 5 (P = 0 3 (P = 0 RP	3 54 3 14 ■ 103 = 0.24); I <sup>#</sup> .01) no-TU	736 76 1139 = 27%	9.1% 57.4% 14.9% 100.0%	5 2.0 5 1.1 5 0.8 6 <b>1.4</b> Ri <u>t M-H, </u>	06 [0.91, 4.67] 15 [0.75, 1.75] 86 [0.36, 2.05] 5 [1.08, 1.95] sk Ratio Fixed, 95% CI	0.1	
2015 TugCu 2021 Bannurah 2022 Garg Total (95% CI) Total events Heterogeneity: Chi <sup>2</sup> Test for overall effec F. marjor comp <u>Study or Subgroup</u> 2012 Zugor	10 31 6 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	1 368 554 3 = 5 (P = 0 3 (P = 0 8 RP <u>s Total</u> 4 80	3 54 3 14 4 103 = 0.24); I <sup>2</sup> .01) <u>no-TU</u> <u>I Events</u> 0 2	736 76 1139 = 27% IRP <u>Total</u> 80	9.1% 57.4% 14.9% 100.0% <u>Weight</u> 37.8%	5 2.0 5 1.1 5 0.8 6 <b>1.4</b> <b>Ri</b> <u>t M-H,</u> 5 2.00	16 [0.91, 4.67] 5 [0.75, 1.75] 36 [0.36, 2.05] 5 [1.08, 1.95] sk Ratio <u>Fixed, 95% Cl</u> 0 [0.38, 10.61]	0.1	Favours TURP Favours no-TURP Risk Ratio
2015 Tugću 2021 Bannurah 2022 Garg Total (95% CI) Total events Heterogeneity: Chi <sup>2</sup> Test for overall effec <b>F. marjor comp</b> <u>Study or Subgroup</u> 2012 Zugor 2014 Hung	1( 31 6 = 6.81, df :t: Z = 2.48 olicatio TUI Events	1 368 554 3 = 5 (P = 3 (P = 0. 8 (P = 0. 0 <b>n</b> <b>RP</b> <u><b>s</b> Total</u> 4 80 3 18	3 54 3 14 103 = 0.24);   <sup>2</sup> .01) <b>no-TU</b> <u>I Events</u> 0 2 5 2	736 76 1139 = 27% IRP Total 80 184	9.1% 57.4% 14.9% 100.0% <u>Weight</u> 37.8% 6.0%	5 2.0 5 1.1 5 0.8 6 <b>1.4</b> 8 <b>Ri</b> <u>t M-H.</u> 5 2.00 5 17.25	16 [0.91, 4.67] 15 [0.75, 1.75] 16 [0.36, 2.05] 15 [1.08, 1.95] 16 [1.08, 1.95] 16 [1.08, 1.95] 17 [1.08, 1.95] 17 [1.03, 10.61] 17 [1.03, 10.61] 18 [1.11, 95.83]	0.1	Favours TURP Favours no-TURP Risk Ratio
2015 Tugću 2021 Bannurah 2022 Garg Total (95% CI) Total events Heterogeneity: Chi <sup>2</sup> Test for overall effec F. marjor comp Study or Subgroup 2012 Zugor 2014 Hung 2015 Tugcu	1( 31 6 = 6.81, df tt Z = 2.48 oblicatio TUI Events	1 368 554 3 = 5 (P = 3 (P = 0 0 RP <u>s Total</u> 4 80 3 16 5 25	3 54 3 14 103 = 0.24); P 001) <b>no-TU</b> <u>I Events</u> 0 2 5 2 5 2	736 76 1139 = 27% IRP Total 80 184 36	9.1% 57.4% 14.9% <b>100.0%</b> <u>Weight</u> 37.8% 6.0% 31.0%	5 2.0 5 1.1 5 0.8 6 <b>1.4</b> 6 <b>1.4</b> 7 2.00 5 17.25 5 3.60	16 [0.91, 4.67] 5 [0.75, 1.75] 36 [0.36, 2.05] 5 [1.08, 1.95] sk Ratio <u>Fixed, 95% C1</u> 0 [0.38, 10.61] 5 [3.11, 95.83] 5 [0.76, 17.10]	0.1	Favours TURP Favours no-TURP Risk Ratio
2015 Tugću 2021 Bannurah 2022 Garg Total (95% CI) Total events Heterogeneity: Chi <sup>T</sup> Test for overall effect <b>F. marjor comp</b> <u>Study or Subgroup</u> 2012 Zugor 2014 Hung 2015 Tugcu 2015 Tugcu	1( 31 6 = 6.81, df :t: Z = 2.48 olicatio TUI Events	1 368 554 3 5554 3 (P = 0 3 (P = 0 3 (P = 0 3 (P = 0 3 (P = 0 4 80 3 18 5 26 3 38	3 54 3 14 103 = 0.24); I <sup>+</sup> ; 0 1) <b>no-TU</b> <b>I Events</b> 2 2 3 2 3 2	736 76 1139 = 27% RP Total 80 184 36 76	9.1% 57.4% 14.9% <b>100.0%</b> <b>Weight</b> 37.8% 6.0% 31.0% 25.2%	5 2.0 5 1.1 5 0.8 6 <b>1.4</b> 6 <b>1.4</b> 7 <b>Ri</b> 7 <b>K</b> 7 <b>K</b> <b>K</b> <b>K</b> <b>K</b> <b>K</b> <b>KKKKKKKKKKKKK</b>	16 [0.91, 4.67] 5 [0.75, 1.75] 16 [0.36, 2.05] 5 [1.08, 1.95] 5 [1.08, 1.95] 5 [1.08, 1.95] 10 [0.38, 10.61] 5 [3.11, 95.83] 10 [0.76, 17.10] 10 [0.52, 17.20]	0.1	Favours TURP Favours no-TURP Risk Ratio
2015 Tugću 2021 Bannurah 2022 Garg Total (95% CI) Total events Heterogeneity: Chi <sup>P</sup> Test for overall effec F. marjor comp Study or Subgroup 2012 Zugor 2014 Zugor 2015 Tugcu 2015 Tugcu 2015 Gugcu 2015 Qarg	1( 31 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	1 368 554 3 = 5 (P = 0 3 (P = 0 <b>n</b> <b>RP</b> <b>s Tota</b> 4 80 3 16 5 26 3 38 159	3 54 3 14 1 103 = 0.24); (F: .01) no-TU <u>I Events</u> 0 2 5 2 3 2 0	736 76 1139 = 27% RP Total 80 184 36 76	9.1% 57.4% 14.9% <b>100.0%</b> <u>Weight</u> 37.8% 6.0% 31.0%	5 2.0 5 1.1 5 0.8 6 <b>1.4</b> 6 <b>1.4</b> 7 <b>Ri</b> 7 <b>K</b> 7 <b>K</b> <b>K</b> <b>K</b> <b>K</b> <b>K</b> <b>KKKKKKKKKKKKK</b>	16 [0.91, 4.67] 5 [0.75, 1.75] 36 [0.36, 2.05] 5 [1.08, 1.95] sk Ratio <u>Fixed, 95% C1</u> 0 [0.38, 10.61] 5 [3.11, 95.83] 5 [0.76, 17.10]	l	Favours TURP Favours no-TURP Risk Ratio
2015 Tugʻu 2021 Bannurah 2022 Garg Total (95% CI) Total events Heterogenelly: Chi <sup>2</sup> Test for overail effec F. marjor comp Study or Subgroup 2012 Zugor 2014 Tugou 2015 Tugou 2015 Tugou 2015 Tugou 2015 CI) Total events Heterogenelly: Chi <sup>2</sup>	10 31 6 73 = 6.81, df tt Z = 2.46 <b>blicatio</b> <b>Events</b> 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	1 368 5 38 5 54 3 5 5 (P = 0 3 (P = 0 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	3 54 3 14 103 = 0.24); I <sup>2</sup> ; 01) no-TU <u>I Events</u> 3 2 5 2 3 2 9 8 = 0.30); I <sup>2</sup> ;	736 76 1139 = 27% RP <u>Total</u> 80 184 376 376	9.1% 57.4% 14.9% <b>100.0%</b> <b>Weight</b> 37.8% 6.0% 31.0% 25.2%	5 2.0 5 1.1 5 0.8 6 <b>1.4</b> 6 <b>1.4</b> 7 <b>Ri</b> 7 <b>K</b> 7 <b>K</b> <b>K</b> <b>K</b> <b>K</b> <b>K</b> <b>KKKKKKKKKKKKK</b>	16 [0.91, 4.67] 5 [0.75, 1.75] 16 [0.36, 2.05] 5 [1.08, 1.95] 5 [1.08, 1.95] 5 [1.08, 1.95] 10 [0.38, 10.61] 5 [3.11, 95.83] 10 [0.76, 17.10] 10 [0.52, 17.20]		Favours TURP Favours no-TURP
2015 Tugʻu 2021 Bannurah 2022 Garg Total (95% CI) Total events Heterogenelly: Chi <sup>2</sup> Test for overail effec F. marjor comp Study or Subgroup 2012 Zugor 2014 Tugou 2015 Tugou 2015 Tugou 2015 Tugou 2015 CI) Total events Heterogenelly: Chi <sup>2</sup>	10 31 6 73 = 6.81, df tt Z = 2.46 <b>blicatio</b> <b>Events</b> 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	1 368 5 38 5 54 3 5 5 (P = 0 3 (P = 0 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	3 54 3 14 103 = 0.24); I <sup>2</sup> ; 01) no-TU <u>I Events</u> 3 2 5 2 3 2 9 8 = 0.30); I <sup>2</sup> ;	736 76 1139 = 27% RP <u>Total</u> 80 184 376 376	9.1% 57.4% 14.9% <b>100.0%</b> <b>Weight</b> 37.8% 6.0% 31.0% 25.2%	5 2.0 5 1.1 5 0.8 6 <b>1.4</b> 6 <b>1.4</b> 7 <b>Ri</b> 7 <b>K</b> 7 <b>K</b> <b>K</b> <b>K</b> <b>K</b> <b>K</b> <b>KKKKKKKKKKKKK</b>	16 [0.91, 4.67] 5 [0.75, 1.75] 16 [0.36, 2.05] 5 [1.08, 1.95] 5 [1.08, 1.95] 5 [1.08, 1.95] 10 [0.38, 10.61] 5 [3.11, 95.83] 10 [0.76, 17.10] 10 [0.52, 17.20]	0.1 1 0.01	Favours TURP Favours no-TURP Risk Ratio
2015 Tugću 2021 Bannurah 2022 Garg Total (95% CI) Total events Heterogeneily: CHI <sup>2</sup> Test for overall effec <b>F. marjor comp</b> <u>Study or Subgroup</u> 2012 Zugor 2014 Tugcu 2015 CI) Total events Heterogeneily: ChI <sup>2</sup> Test for overall effec	10 33 55 56.81, df 55 50 50 50 50 50 50 50 50 50 50 50 50	1 368 5 38 5 54 3 (P = 0 9 (P = 0 9 (P = 0 9 (P = 0 9 (P = 0 159 5 = 3 (P = 0 5 (P = 0 159 5 (P = 0 159 5 = 3 (P = 0 159 159 159 159 159 159 159 159	3 54 3 14 103 = 0.24); (°. 0.1) no-TU <u>I Events</u> 0 2 5 2 5 2 3 2 9 8 = 0.30); (°.	736 76 76 1139 = 27% 80 184 36 76 376 = 19%	9.1% 57.4% 14.9% <b>100.0%</b> <b>Weight</b> 37.8% 6.0% 31.0% 25.2%	2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0	16 [0.91, 4.67] 15 [0.75, 1.75] 16 [0.36, 2.05] 15 [1.08, 1.95] 10 [1.		Favours TURP Favours no-TURP
2015 Tugću 2021 Bannurah 2022 Garg Total (95% CI) Total events Heterogenelly: Chi <sup>2</sup> Test for overall effec F. marjor comp Study or Subgroup, 2012 Zugor 2014 Hung 2015 Tugcu 2022 Garg Total (95% CI) Total events Heterogenelly: Chi <sup>2</sup> Test for overall effec G. bladder nec Study or Subgroup	1( 3) 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	i 366 554 554 3 i=5 (P=0 <b>n</b> <b>RP</b> <b>s</b> Total 4 80 3 16 5 25 5 25 5 3 36 <b>i</b> 159 5 5 5 3 (P=0 <b>i</b> 159 5 25 5 3 36 <b>i</b> 159 5 5 5 4 80 <b>i</b> 159 5 5 5 7 5 7 5 7 5 7 5 7 5 7 5 7	3 54 3 14 103 = 0.24); (* no-TU <u>I Events</u> 3 2 5 2 3 2 9 8 = 0.30); (* .002) No-TUE Events	736 76 76 1139 = 27% RP <u>Total</u> 80 184 80 184 36 76 376 = 19% 8P Total	9.1% 57.4% 14.9% 100.0% 37.8% 6.0% 31.0% 25.2% 100.0%	<ul> <li>2.0</li> <li>1.1</li> <li>0.8</li> <li>1.4</li> <li>Rii</li> <li>1.4</li> <li>Rii</li> <li>1.4</li> <li>Rii</li> <li>1.4</li> <li>Rii</li> <li>1.4</li> <li>Rii</li> <li>1.4</li> <li>Rii</li> <li>3.60</li> <li>3.60</li> <li>3.60</li> <li>3.60</li> <li>8</li> <li>Rii</li> <li>M-H, R</li> <li>Ri</li> </ul>	16 [0.91], 4.67] 16 [0.36, 2.05] 15 [1.08, 1.95] 15 [1.08, 1.95] 10 [0.38, 10.61] 13 [1.1, 95.8] 10 [0.52, 17.20] 17 [1.63, 8.24] 18 Katio andom, 95% CI	0.01	Favours TURP Favours no-TURP
2015 Tugću 2021 Bannurah 2022 Garg Total (95% CI) Total events Heterogeneity, Chi <sup>2</sup> Test for overall effec <b>F. marjor comp</b> <u>Study or Subgroup</u> 2012 Zugor 2014 Hung 2015 Tugcu 2014 Fungcu 2015 Tugcu 2014 Garg Total (95% CI) Total events Heterogeneity, Chi <sup>2</sup> Test for overall effec <b>G. bladder neco</b> <u>Study or Subgroup</u>	1( 3) ( = 6.81, df tt Z = 2.48 ( ct Z = 2.48 ( ct Z = 3.48) ( ct Z = 3.69, df tt Z = 3.16 ( ct Z = 3.16 ( ct Z = 3.16) ( ct Z	i 366 554 554 3 = 5 (P = 0 in n RP RP 159 5 5 5 5 5 5 5 5 6 (P = 0 ir RP 27 7 5 5 5 6 (P = 0 159 16 16 16 16 16 16 16 16 16 16	3 54 3 14 1 103 = 0.24); I <sup>+</sup> : 0.01) no-TU <u>Events</u> 3 2 3 2 3 2 9 8 = 0.30); I <sup>+</sup> : 0.02) no-TUF <u>Events</u> 3	736 76 76 1139 = 27% RP <u>Total</u> 80 184 36 76 376 = 19% RP <u>Total</u> 27	9.1% 57.4% 14.9% 100.0% 37.8% 6.0% 25.2% 100.0% Weight 12.9%	<ul> <li>2.0</li> <li>1.1</li> <li>0.8</li> <li>1.4</li> <li>1.4</li></ul>	16 [0.91; 4.67] 15 [0.76, 1.75] 16 [0.36, 2.06] 15 [1.08, 1.95] 16 [0.36, 2.06] 17 [1.08, 1.95] 10 [0.52, 17.20] 17 [1.63, 8.24] 18 Ratio andom, 95% CI 17 [1.15, 11.68]	0.01	Favours TURP Favours no-TURP Risk Ratio M-H, Fixed, 95% CI 0.1 0.1 10 100 Favours TURP Favours no-TURP Risk Ratio
2015 Tugću 2021 Bannurah 2022 Garg Total (95% CI) Total events Heterogenelly: Chi <sup>2</sup> Test for overall effec F. marjor comp Study or Subaroup, 2012 Zugor 2014 Hung 2015 Tugcu 2022 Garg Total (95% CI) Total events Heterogenelly: Chi <sup>2</sup> Test for overall effec G. bladder nec Study or Subaroup 2010 Apdali 2011 Gupta	11( 31) 51) 51) 51) 51) 51) 51) 51) 51) 51) 5	1 366 3 3 554 3 $= 5 (P = 0$ 8 $(P = 0$ <b>n</b> <b>n</b> <b>n</b> <b>n</b> <b>n</b> <b>n</b> <b>n</b> <b>n</b>	3 54 3 14 1 103 = 0.24); [P; .01) no-TU <u>Fevents</u> 0 2 5 2 3 2 8 = 0.30); [P; .002) <u>no-TUF</u> <u>Events</u> 3 13	736 76 76 1139 = 27% 80 184 36 76 376 376 376 376 376 376 27 132	9.1% 57.4% 14.9% 100.0% 0.0% 37.8% 6.0% 31.0% 25.2% 100.0% Weight 12.9%	<ul> <li>2.0</li> <li>1.1</li> <li>0.8</li> <li>1.4</li> <li>Ri</li> <li>Ri</li> <li>2.00</li> <li>17.2</li> <li>3.60</li> <li>3.60</li> <li>Ri</li> <li>M-H, R</li> <li>3.1</li> <li>3.6</li> </ul>	16 [0.91], 4.67] 16 [0.36, 2.05] 15 [1.08, 1.95] 15 [1.08, 1.95] 16 [0.38, 10.61] 10 [0.38, 10.61] 10 [0.38, 10.61] 10 [0.38, 10.61] 10 [0.52, 17.20] 17 [1.63, 8.24] 18 [0.76, 17.60] 19 [0.52, 17.20] 17 [1.63, 8.24] 19 [0.52, 17.20] 19 [0.52, 17.20] 19 [0.52, 17.20] 19 [0.52, 17.20] 19 [0.52, 17.20] 10 [0.52, 17.20]	0.01	Favours TURP Favours no-TURP Risk Ratio M-H, Fixed, 95% CI 0.1 0.1 10 100 Favours TURP Favours no-TURP Risk Ratio
2015 Tugću 2021 Bannurah 2022 Garg Total (95% CI) Total events Heterogenely: Chi <sup>2</sup> Test for overall effec <b>F. marjor comp</b> Study or Subgroup 2012 Zugor 2014 Hung 2015 Tugcu 2015 August 2014 Garg 2014 Garg 2014 Hung 2015 CI) Total events Heterogenelty: Chi <sup>2</sup> Test for overall effec <b>G. bladder neco</b> Study or Subgroup 2010 Abedall 2010 Abedall 2011 Zugor	10 31 31 55 56 50 50 50 50 50 50 50 50 50 50 50 50 50	i 366 554 554 3 3 554 8 (P = 0 <b>n</b> <b>RP</b> <b>s</b> <b>to</b> <b>s</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b> <b>to</b>	3 54 3 14 1 103 = 0.24); [P: .01) no-TU Events 3 2 5 2 3 2 9 8 = 0.30); [P: .002) no-TUF Events 3 13 2	736 76 76 1139 = 27% 80 80 80 184 36 76 376 376 = 19% 80 80	9.1% 57.4% 14.9% 100.0% Weight 100.0% 31.0% 25.2% 100.0% Weight 12.9% 16.6%	<ul> <li>2.0.5</li> <li>1.1.1</li> <li>0.8</li> <li>1.4</li> <li>Rii</li> <li>M-H, 6</li> <li>3.60</li> <li>3.60</li> <li>8</li> <li>M-H, R</li> <li>3.1</li> <li>3.2</li> <li>2.3</li> <li>2.3</li> </ul>	16 [0.91; 4.67] 15 [0.76, 1.75] 16 [0.36, 2.03] 15 [1.08, 1.95] 16 [1.08, 1.95] 17 [1.08, 1.95] 18 [1.10, 1.95] 19 [1.10, 1.95] 19 [1.10, 1.95] 10 [1.10, 1.95] 10 [1.10, 1.95] 10 [1.10, 1.95] 11 [1.10, 1.95] 11 [1.10, 1.95] 11 [1.10, 1.95] 12 [1.10, 1.10, 1.95] 13 [1.10, 1.10,	0.01	Favours TURP Favours no-TURP Risk Ratio M-H, Fixed, 95% CI 0.1 0.1 10 100 Favours TURP Favours no-TURP Risk Ratio
2015 Tugću 2021 Bannurah 2022 Garg Total (95% CI) Total events Heterogenel%; Chi <sup>9</sup> Test for overall effec <b>F. marjor comp</b> Study or Subgroup 2012 Zugor 2012 Zugor 2013 Zugor 2013 Zugor 2014 Hung 2015 Tugcu 2022 Garg Total (95% CI) Total events Heterogenel%; Chi <sup>9</sup> Test for overall effec <b>G. bladder nec</b> Study or Subgroup 2010 Apddall 2011 Gupta 2012 Jugor 2014 Hung	11( 31) 51) 51) 51) 51) 51) 51) 51) 51) 51) 5	i 366 554 554 3 3 554 8 (P = 0 <b>nn</b> <b>RP</b> <b>s</b> Total 4 86 5 225 5 (P = 0 <b>ir</b> 5 (P = 0 <b>ir</b> 7 (P = 0 <b>ir</b> 80 159 5 (P = 0 <b>ir</b> 159 5 (P = 0) 159 5 (P = 0) 159 159 159 159 159 159 159 159	3 54 3 14 1 103 = 0.24); [P; .01) no-TU <u>Fevents</u> 0 2 5 2 3 2 8 = 0.30); [P; .002) <u>no-TUF</u> <u>Events</u> 3 13	736 76 76 1139 = 27% 80 184 36 76 376 376 376 376 376 376 27 132	9.1% 57.4% 14.9% 100.0% 0.0% 37.8% 6.0% 31.0% 25.2% 100.0% Weight 12.9%	<ul> <li>2.0</li> <li>1.1</li> <li>1.1</li> <li>0.6</li> <li>1.4</li> <li>Ri</li> <li>T.M-H.</li> <li>7.00</li> <li>1.7.22</li> <li>3.60</li> <li>3.60</li> <li>3.60</li> <li>3.60</li> <li>3.60</li> <li>8</li> <li>M-H.R</li> <li>3.10</li> <li>2.23%</li> <li>6</li> </ul>	16 [0.91], 4.67] 16 [0.36, 2.05] 5 [1.08, 1.95] 5 [1.08, 1.95] 5 [1.08, 1.95] 5 [1.08, 1.95] 5 [0.38, 10.61] 10 [0.38, 10.61] 10 [0.38, 10.61] 10 [0.52, 17.20] 7 [1.63, 8.24] 5 [1.16, 11.69] 5 [2.11, 4.6, 38] 5 [5.11, 9.3, 48] 5 [5.12] (3.4, 6) 5 [5.12] (3.4, 6)	0.01	Favours TURP Favours no-TURP Risk Ratio M-H, Fixed, 95% CI 0.1 0.1 10 100 Favours TURP Favours no-TURP Risk Ratio
2015 Tugću 2021 Bannurah 2022 Garg Total (95% CI) Total events Heterogeneity: Chi <sup>2</sup> Test for overall effec F. marjor comp Study or Subgroup 2012 Zugor 2014 Hung 2015 Tugću 2022 Garg Total events Heterogeneity: Chi <sup>2</sup> Test for overall effec G. bladdet necc Study or Subgroup 2010 Abedali 2011 Qugta 2012 Zugor 2014 Alung 2014 Alung 2015 Gellhaus	10 31 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	i 366 554 3 554 3 554 3 5 5 5 5 5 5 5 5 5 5 7 159 5 5 7 159 5 5 7 159 159 159 159 159 159 159 169 169 169 169 169 169 169 16	54 54 54 54 54 54 54 54 54 54	736 76 76 1139 = 27% 80 184 36 76 376 376 = 19% 80 184 27 132 80 184	9.1% 57.4% 14.9% 100.0% 37.8% 6.0% 31.0% 25.2% 100.0% Weight 12.9% 16.6% 10.4%	<ul> <li>2.0.5</li> <li>1.1.1</li> <li>0.8</li> <li>0.8</li> <li>1.4</li> <li>Rit</li> <li>M-H, B</li> <li>2.00</li> <li>3.66</li> <li>3.60</li> <li>3.66</li> <li>3.60</li> <li>8.6</li> <li>Rit</li> <li>3.00</li> <li>3.61</li> </ul>	16 [0.91; 4.67] 15 [0.76, 1.75] 16 [0.36, 2.03] 15 [1.08, 1.95] 16 [1.08, 1.95] 17 [1.08, 1.95] 18 [1.10, 1.95] 19 [1.10, 1.95] 19 [1.10, 1.95] 10 [1.10, 1.95] 10 [1.10, 1.95] 10 [1.10, 1.95] 11 [1.10, 1.95] 11 [1.10, 1.95] 11 [1.10, 1.95] 12 [1.10, 1.10, 1.95] 13 [1.10, 1.10,	0.01	Favours TURP Favours no-TURP Risk Ratio M-H, Fixed, 95% CI 0.1 0.1 10 100 Favours TURP Favours no-TURP Risk Ratio
2015 Tugću 2021 Bannurah 2022 Garg Total (95% CI) Total events Heterogenely, Chi <sup>a</sup> Test for overall effec <b>F. marjor comp</b> Study or Subgroup, 2012 Zugor 2014 Hung 2015 Tugcu 2022 Garg Total (95% CI) Total events Heterogenely, Chi <sup>a</sup> Test for overall effec <b>G. bladder neco</b> Study or Subgroup 2010 Abedali 2011 August 2011 Zugor 2012 Zugor 2012 Zugor 2014 Hung 2015 Tugcu	11 11 11 12 14 15 14 15 15 16 17 17 17 17 17 17 17 17 17 17	i 366 5 36 554 3 = 5 (P = 0 8 (P = 0 n RP 8 Total 8 (P = 0 n RP 155 5 = 3 (P = 0 155 5 (P = 0 ir 27 5 (P = 0 ir 27 15 8 (P = 0 155 5 (P = 0 155 155 155 155 155 155 155 155 155 15	54 54 54 54 54 54 54 54 54 54	736 76 76 1139 = 27% 80 184 36 76 376 = 19% 80 87 7 132 80 184 22	9.1% 57.4% 57.4% 14.9% 100.0% Weight 100.0% Weight 12.9% 100.0% Weight 12.9% 10.6% 8.2%	<ul> <li>2.0.5</li> <li>1.1.1</li> <li>6</li> <li>1.4</li> <li>1.4</li> <li>1.4</li> <li>1.4</li> <li>2.00</li> <li>1.7.22</li> <li>3.60</li> <li>3.60</li> <li>8</li> <li>8</li> <li>8</li> <li>8</li> <li>8</li> <li>8</li> <li>9</li> <li>1.4</li> <li>1.4</li> </ul>	ls [0.91, 4.67] 5 [0.75, 1.75] 5 [0.75, 1.75] 5 [1.08, 1.95] 5 [1.08, 1.95	0.01	Favours TURP Favours no-TURP Risk Ratio M-H, Fixed, 95% CI 0.1 0.1 10 100 Favours TURP Favours no-TURP Risk Ratio
2015 Tugću 2021 Bannurah 2022 Garg Total (95% CI) Total events Heterogenely, Chi <sup>a</sup> Test for overall effec <b>F. marjor comp</b> Study or Subgroup, 2012 Zugor 2014 Hung 2015 Tugcu 2022 Garg Total (95% CI) Total events Heterogenely, Chi <sup>a</sup> Test for overall effec <b>G. bladder neco</b> Study or Subgroup 2010 Abedaii 2011 Aung 2015 Tugcu 2015 Tugcu 2015 Tugcu	11( 31) 7: 7: 7: 7: 7: 7: 7: 7: 7: 7: 7: 7: 7:	i 366 5 36 554 3 = 5 (P = 0 8 (P = 0 n RP 8 Total 8 (P = 0 n RP 155 5 = 3 (P = 0 155 5 (P = 0 ir 27 5 (P = 0 ir 27 15 8 (P = 0 155 5 (P = 0 155 155 155 155 155 155 155 155 155 15	54 54 54 54 54 54 54 54 54 54	736 76 76 1139 = 27% <b>Total</b> 80 184 36 76 376 = 19% <b>Exp</b> 132 80 184 132 80 184 27 76	9.1% 57.4% 14.9% 100.0% 37.8% 6.0% 31.0% 25.2% 100.0% Weight 12.9% 16.6% 8.2% 8.2%	<ul> <li>2.0.5</li> <li>2.1.1</li> <li>5</li> <li>2.6</li> <li>1.1.1</li> <li>5</li> <li>0.8</li> <li>6</li> <li>1.4</li> <li>1.4</li> <li>3</li> <li>3.6</li> <li>3.0</li> <li>4.4</li> <li>3</li> </ul>	16 [0.91; 4.67] 15 [0.75, 1.75] 16 [0.36, 2.06] 16 [0.36, 2.06] 16 [0.36, 2.06] 17 [0.38, 10.61] 17 [0.38, 10.61] 17 [1.6, 1.62] 19 [0.76, 17.10] 10 [0.52, 17.20] 7 [1.63, 8.24] 10 [0.76, 17.10] 10 [0.52, 17.20] 7 [1.63, 8.24] 10 [0.63, 8.64] 10 [0.64, 15.41] 10 [0.38, 5.64] 10 [0.38, 5.54] 10 [0.38, 5.55] 10	0.01 0.01 1 1 1 1 1 1 1	Favours TURP Favours no-TURP Risk Ratio M-H, Fixed, 95% CI 0.1 0.1 10 100 Favours TURP Favours no-TURP Risk Ratio
2015 Tugću 2021 Bannurah 2022 Garg Total (95% CI) Total events Heterogeneity, Chi <sup>2</sup> Test for overall effec <b>F. marjor comp</b> Study or Subgroup 2012 Zugor 2014 Hung 2015 Tugcu 2022 Garg Total (95% CI) Total events Heterogeneity, Chi <sup>2</sup> Test for overall effec <b>G. bladder necu</b> 2010 Abedall 2011 August 2015 Zugor 2014 Hung 2015 Tugcu 2015 Gelfaus 2015 Tugcu 2015 Gelfaus 2015 Tugcu 2015 Gelfaus	111 313 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	1 366 5 36 554 3 = 5 (P = 0 8 (P = 0 m RP 5 Total 6 (P = 0 m RP 5 22 5 3 36 5 22 5 3 36 5 22 5 3 36 5 3 36 5 3 8 5 3 8 159 5 6 (P = 0 159 5 6 (P = 0 169 169 169 169 169 169 169 169	3 5 4 3 14 103 = 0.24); <sup>p</sup> . 109 = 0.24); <sup>p</sup> . 109 = 0.20); <sup>p</sup> . 109 = 0.20); <sup>p</sup> . 109 = 0.20); <sup>p</sup> . 109 = 0.20); <sup>p</sup> . 109 = 0.20;	736 76 76 1139 = 27% <b>Total</b> 376 376 = 19% 80 80 80 82 80 80 184 22 36 76 376 557	9.1% 57.4% 14.9% 100.0% <i>Weightt</i> 12.9% 100.0%	<ul> <li>2.0.5</li> <li>1.1.1</li> <li>0.8.8</li> <li>1.4</li> <li>Ri</li> <li>Ri</li> <li>17.24</li> <li>3.66</li> <li>3.00</li> <li>3.66</li> <li>3.00</li> <li>3.66</li> <li>3.00</li> <li>3.61</li> <li>4.61</li> <li>5.61</li> </ul>	16 [0.11; 4.67] 15 [0.76, 1.75] 16 [0.76, 1.75] 16 [0.36, 2.06] 15 [1.08, 1.95] 10 [10, 10, 10, 10] 10 [10, 10, 10, 10] 10 [11, 10] 1	0.01 0.01 1 1 1 1 1 1 1	Favours TURP Favours no-TURP Risk Ratio M-H, Fixed, 95% CI 0.1 0.1 10 100 Favours TURP Favours no-TURP Risk Ratio
2015 Tugću 2021 Bannurah 2022 Garg Total (95% CI) Total events Heterogenelly: Chi <sup>3</sup> Test for overall effec <b>F. marjor comp</b> Study or Subgroup, 2012 Zugor 2014 Hung 2015 Tugcu 2022 Garg Total (95% CI) Total events Heterogenelly: Chi <sup>3</sup> Test for overall effec <b>G. bladder nec</b> Study or Subgroup 2010 Abedail 2011 Gupta 2011 Gupta 2012 Garg 2014 Hung 2015 Gellhaus 2015 Tugcu 2013 Gupta 2014 Jung 2015 Gellhaus 2015 Tugcu 2014 Jung 2015 Sugcu 2014 Jung 2015 Sugcu 2014 Jung 2015 Sugcu 2014 Hung 2015 Sugcu 2014 Sugcu 2015 Sugcu 2014 Sugcu 2015 Sugcu 2014 Sugcu 2015 Sugcu 2016 Sugcu 2016 Sugcu 2017 Sugcu 2017 Sugcu 2018 Sugcu 2018 Sugcu 2018 Sugcu 2018 Sugcu 2018 Sugcu 2018 Sugcu 2018 Sugcu 2018 Sugcu 2018 Sugcu 2019 Sugcu 20	111 111 111 111 111 111 111 111	i 366 554 3 554 3 554 8 (P = 0 m RP 8 (P = 0 m RP 8 (P = 0 m 155 5 (P = 0 155 5 (P = 0 165 5 (P = 0 155 5 (P = 0 155 155 155 155 155 155 155 15	3 5 4 3 14 103 102 102 102 102 102 102 102 102	736 76 76 1139 = 27% <b>Total</b> 376 376 = 19% 80 80 80 82 80 80 184 22 36 76 376 557	9.1% 57.4% 14.9% 100.0% <i>Weightt</i> 12.9% 100.0%	<ul> <li>2.0.5</li> <li>1.1.1</li> <li>0.8.8</li> <li>1.4</li> <li>Ri</li> <li>Ri</li> <li>17.24</li> <li>3.66</li> <li>3.00</li> <li>3.66</li> <li>3.00</li> <li>3.66</li> <li>3.00</li> <li>3.61</li> <li>4.61</li> <li>5.61</li> </ul>	16 [0.11; 4.67] 15 [0.76, 1.75] 16 [0.76, 1.75] 16 [0.36, 2.06] 15 [1.08, 1.95] 10 [10, 10, 10, 10] 10 [10, 10, 10, 10] 10 [11, 10] 1	0.01 0.01 1 1 1 1 1 1 1	Favours TURP Favours no-TURP Risk Ratio M.H. Fixed, 95% CI 0.1 Favours TURP Favours no-TURP Risk Ratio M.H. Random, 95% CI 0.1 0.1 0.1 0.5 0.1 0.5 0.1 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5
2015 Tugću 2021 Bannurah 2022 Garg Total (95% CI) Total events Heterogenelly: Chi <sup>3</sup> Test for overall effec <b>F. marjor comp</b> Study or Subgroup, 2012 Zugor 2014 Hung 2015 Tugću 2022 Garg Total (95% CI) Total events Heterogenelly: Chi <sup>3</sup> Test for overall effec <b>S. bladder nec</b> <b>Study or Subgroup</b> 2010 Abedali 2011 Gupta 2015 Tugću 2015 Tugću	111 111 111 111 111 111 111 111	i 366 554 3 554 3 554 8 (P = 0 m RP 8 (P = 0 m RP 8 (P = 0 m 155 5 (P = 0 155 5 (P = 0 165 5 (P = 0 155 5 (P = 0 155 155 155 155 155 155 155 15	3 5 4 3 14 103 102 102 102 102 102 102 102 102	736 76 76 1139 = 27% <b>Total</b> 376 376 = 19% 80 80 80 82 80 80 184 22 36 76 376 557	9.1% 57.4% 14.9% 100.0% <i>Weightt</i> 12.9% 100.0%	<ul> <li>2.0.5</li> <li>1.1.1</li> <li>0.8.8</li> <li>1.4</li> <li>Ri</li> <li>Ri</li> <li>17.24</li> <li>3.66</li> <li>3.00</li> <li>3.66</li> <li>3.00</li> <li>3.66</li> <li>3.00</li> <li>3.61</li> <li>4.61</li> <li>5.61</li> </ul>	16 [0.11; 4.67] 15 [0.76, 1.75] 16 [0.76, 1.75] 16 [0.36, 2.06] 15 [1.08, 1.95] 10 [10, 10, 10, 10] 10 [10, 10, 10, 10] 10 [11, 10] 1	0.01	Favours TURP Favours no-TURP
2015 Tugću 2021 Bannurah 2022 Garg Total (95% CI) Total events Heterogenelly: Chi <sup>3</sup> Test for overall effec <b>F. marjor comp</b> <u>Study or Subgroup</u> 2012 Zugor 2014 Hung 2015 Tugcu 2022 Garg Total (95% CI) Total events Heterogenely: Chi <sup>3</sup> Test for overall effec <b>G. bladder nec</b> <u>Study or Subgroup</u> 2016 Quila 2015 Gellnaus 2015 Gellnaus 2016 Genter Test for overall effect <b>H. nerves spare</b>	111 111 111 111 111 111 111 111	3686 36767 367677 3677777 3777777777777777777777777777777777777	3 5 4 3 14 103 102 102 102 102 102 102 102 102	736 76 76 1139 = 27% 80 184 36 76 376 = 19% 82P Total 27 184 22 36 76 76 557 (P = 0.0	9.1% 57.4% 14.9% 100.0% 100.0% 37.8% 6.0% 25.2% 100.0% 10.6% 8.2% 10.4% 8.2% 10.4% 8.2% 10.4% 8.2% 11.4%	<ul> <li>2.2.5</li> <li>2.1.6</li> <li>2.0.5</li> <li>0.8</li> <li>0.8</li> <li>1.4</li> <li>Rit</li> <li>RH.H, 3.1</li> <li>2.0</li> <li>3.66</li> <li>3.66</li> <li>3.00</li> <li>3.6</li> <li>4.7</li> <li>4.8</li> <li>5</li> <li>6</li> <li>6</li> <li>6</li> <li>6</li> <li>7</li> <li>6</li> <li>7</li> <li>7</li> <li>8</li> <li>7</li> <li>8</li> <li>7</li> <li>8</li> <li>7</li> <li>8</li> <li>8</li> <li>8</li> <li>8</li> <li>8</li> <li>8</li> <li>9</li> <li>9</li></ul>	16 [0.91; 4.67] 16 [0.36, 2.05] 15 [1.08, 1.95] 15 [1.08, 1.95] 15 [1.08, 1.95] 10 [0.38, 10.61] 13 [11, 95.83] 10.76, 17.10] 10.52, 17.20] 7 [1.16, 38, 824] 10 [16, 28, 86] 10 [16,	0.01	Favours TURP Favours no-TURP Risk Ratio M.H. Fixed, 95% CI 0.1 10 100 Favours TURP Favours no-TURP Risk Ratio M.H. Random, 95% CI 0.1 10 50 Favours TURP Favours no-TURP Risk Ratio
2015 Tugću 2021 Bannurah 2022 Garg Total (95% CI) Total events Heterogenely, Chi <sup>2</sup> Test for overall effec F. marjor comp Study or Subgroup 2012 Zugor 2014 Hung 2015 Tugću 2022 Garg Total events Heterogenely, Chi <sup>2</sup> Test for overall effec G. bladdel 2010 Abedali 2011 Auga 2015 Gellnaus 2015 Gellnaus 2016 Gellnaus 2017 Gellnaus 2017 Gellnaus 2018 Gell	111 313 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	368         36           5343         3543           5543         3543           3553         3543           3553         3543           55343         316           5523         316           5523         316           5533         365           5533         365           5533         365           5533         365           563         700           770         18           806         311           538         30           538         215           538         215           538         215           538         215           538         215           538         215	<ul> <li>3 5 4 3 14</li> <li>103 20 20 (2014)</li> <li>10 2 2 (2014)</li> <li>10 2 (2014)</li> <li>10 - TUI = Events</li> <li>2 2 5 (2014)</li> <li>2 2 5 (2014)</li> <li>2 2 (2014)</li> <li>2 (2014)</li></ul>	736 76 76 1139 = 27% 80 184 36 76 376 = 19% 8P 127 132 8P 127 132 8P 127 132 8P 127 557 (P = 0.0 184 26 557 (P = 0.0 184 26 76 76 76 76 76 76 76 76 76 76 76 76 76	9.1% 57.4% 14.9% 100.0% 37.8% 25.2% 100.0% 10.4% 26.7% 10.4% 26.7% 10.4% 26.7% 10.4% 10.4% 10.4% 10.4% 10.6% 14.4%	<ul> <li>2.0.5</li> <li>2.0.5</li> <li>1.1.4</li> <li>Rit</li> <li>M.H., R</li> <li>3.00</li> <li>3.76</li> <li>Rit</li> <li>M.H., R</li> <li>3.01</li> <li>3.30</li> <li>S</li> <li>3.3%</li> <li>Rit</li> <li>M.H., R</li> </ul>	In [0.91; 4.67] 15 [0.76, 1.75] 16 [0.76, 1.75] 16 [0.36, 2.06] 15 [1.08, 1.95] 15 [1.08, 1.95] 16 [1.08, 1.95] 17 [1.08, 1.95] 10 [1.15, 1.16] 10 [1.15, 11.69] 10 [1.15, 11.69] 11 [1.15, 11.69] 11 [1.15, 11.69] 12 [1.15, 11.69] 13 [1.15, 11.69] 14 [1.15, 11.69] 14 [1.15, 11.69] 15	0.01	Favours TURP Favours no-TURP Risk Ratio M.H. Fixed, 95% CI 0.1 10 Favours TURP Favours no-TURP Risk Ratio M.H. Random, 95% CI 0.1 10 Favours TURP Favours no-TURP Favours TURP Favours no-TURP Favours TURP Favours no-TURP
2015 Tugću 2021 Bannurah 2022 Garg Total (95% CI) Total events Heterogenel%, Chi <sup>3</sup> Testfor overall effec <b>F. marjor comp</b> Study or Subgroup, 2012 Zugor 2014 Hung 2015 Tugcu 2022 Garg Total (95% CI) Total events Heterogenel%, Chi <sup>3</sup> Test for overall effec <b>G. bladder nec</b> Study or Subgroup, 2016 Sugor 2016 Sugor 2015 Tugcu 2025 Garg Total (95% CI) Total events Heterogenel%, Tau <sup>3</sup> Total (95% CI) Total events Heterogenel%, Tau <sup>3</sup> Test for overall effec <b>H. nervers spar</b> Study or Subgroup 2010 Abedail	111 111 111 111 111 111 111 111	3 = 3 = 3 = 3 = 3 = 3 = 3 = 3 = 3 = 3 =	3 5 4 4 1 103 102 5 2 2 4); P <sup>-</sup> 102 7 1 2 2 4); P <sup>-</sup> 102 7 1 2 2 4 103 7 1 1 2 4 103 7 1 1 2 4 103 7 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	736 76 76 1139 = 27% 80 184 36 76 376 = 19% 82P Total 27 184 22 36 76 76 557 (P = 0.0	9.1% 57.4% 57.4% 14.9% 100.0% 100.0% 37.8% 25.2% 100.0% 10.6% 26.7% 8.2% 8.2% 10.6% 10.6% 14.4% 10.0% 5); P = 5	i         2.0           i         1.1           i         1.1           i         1.4           i         1.4           i         1.7           i         1.7           i         1.7           i         1.7           i         1.7           i         3.00           i         3.6           3.3.0         3.6           3.3.0         3.8           5         3.3%           Rit         M.H.           M.H.         0.0.8	16 [0.91; 4.67] 16 [0.36, 2.05] 15 [1.08, 1.95] 15 [1.08, 1.95] 10 [0.38, 10.61] 10 [0.38, 10.61] 10 [0.38, 10.61] 10 [0.38, 10.61] 10 [0.52, 17.20] 7 [1.53, 8.24] 10 [0.52, 17.20] 7 [1.53, 8.24] 10 [0.52, 17.20] 7 [1.53, 8.24] 10 [0.52, 17.20] 10 [	0.01	Favours TURP Favours no-TURP Risk Ratio M.H. Fixed, 95% CI 0.1 10 100 Favours TURP Favours no-TURP Risk Ratio M.H. Random, 95% CI 0.1 10 50 Favours TURP Favours no-TURP Risk Ratio
2015 Tugću 2021 Bannurah 2022 Garg Total (95% CI) Total events Heterogenely: Chi <sup>2</sup> Test for overall effec F. marjor comp Study or Subgroup 2012 Zugor 2014 Hung 2015 Tugcu 2022 Garg Total (95% CI) Total events Heterogeneity: Chi <sup>2</sup> Test for overall effec G. bladder nec Study or Subgroup 2016 Quinta 2015 Gellnaus 2015 Gellnaus 2016 Gellnaus 2017 Zugor	111 117 117 117 117 117 117 117	3 = 3 = 3 = 3 = 3 = 3 = 3 = 3 = 3 = 3 =	3         5         4           3         14         103           = 0.24); P         10         10           no-TU         no-TU         10           = 0.24); P         2         2           >         2         2         2           >         2         2         2           >         3         2         2           >         8         8         2           >         0.002)         no-TU         10           Events         3         13         2           2         2         5         5           55         55         55           55         55         55           79, df = 6         55         55           79, df = 6         55         55           55         55         55           70, df = 6         55         55           55         55         55           55         55         55           55         55         55           55         55         55           55         55         55           55         55         <	736 76 76 76 76 76 76 80 80 184 36 76 376 577 80 80 80 80 80 80 80 80 80 80 80 80 80	9.1% 57.4\% 57.4\% 57.5\% 57.4\% 57.4\% 57.5\% 57.4\% 57.5\% 57.4\% 57.5\% 57.4\% 57.5\% 57.4\% 57.5\% 57.4\% 57.5\% 57.4\% 57.5\% 57.4\% 57.5\%	<ul> <li>2.0.1</li> <li>2.0.1</li> <li>1.1.4</li> <li>Rit</li> <li>M-H, is</li> <li>2.0.02</li> <li>3.06</li> <li>3.06</li> <li>3.06</li> <li>3.01</li> <li>3.01</li></ul>	In [0.91, 4.67] 5 [0.75, 1.75] 5 [0.75, 1.75] 5 [1.08, 1.95] 5 [1.08, 1.95] 5 [1.08, 1.95] 5 [1.08, 1.95] 5 [1.08, 1.95] 10 [3, 1.1, 95.83] 10.76, 1.71.01 10.72, 1.72.01 7 [1.63, 8.24] 10 [3, 1.1, 95.83] 10 [5, 91, 93.43] 10 [3, 1.1, 95.83] 10 [3, 1.1, 95.83] 11 [3, 1.1, 95.83] 12 [3, 1.1, 95.83] 13 [3, 1.1, 3.1] 13 [0, 0.0, 1.1, 1.34] 13 [0, 0.0, 1.1, 1.34]	0.01	Favours TURP Favours no-TURP Risk Ratio M.H. Fixed, 95% CI 0.1 10 100 Favours TURP Favours no-TURP Risk Ratio M.H. Random, 95% CI 0.1 10 50 Favours TURP Favours no-TURP Risk Ratio
2015 Tugʻu 2021 Bannurah 2022 Garg Total (95% CI) Total events Heterogenelly: Chi <sup>3</sup> Test for overall effec F. marjor comp Study or Subgroup 2012 Zugor 2014 Hung 2015 Tugʻu 2022 Garg Total (95% CI) Total events Heterogenelly: Chi <sup>3</sup> Test for overall effec G. bladder nec Study or Subgroup 2015 Gellnaus 2015 Gellnaus 2015 Gellnaus 2015 Gellaus Total (95% CI) Total effect H. nerves spare Study or Subgroup 2010 Abedali 2010 Subgroup 2010 Abedali 2010 Zugor 2010 Abedali 2010 Zugor 2010 Abedali 2010 Zugor	111 111 111 111 111 111 111 111	3         3           3         3           3         3           3         5           3         7           3         7           8         7           8         7           9         7           10         8           11         5           27         18           80         16           11         12           27         18           80         16           11         12           27         18           80         16           11         12           27         18           80         16           11         12           215         3           215         3           217         18           30         215           37         37           37         37           37         37           37         37           37         37           37         37           37         37           37         37 <td>3         54           3         14           103         14           103         103           e0.24); P         100           non-TU         100           1         20           2         2           3         2           3         3           2         2           5         5           5         5           5         5           5         5           5         5           5         5           5         5           5         5           5         5           5         5           5         5           6         5           10         1</td> <td>736 76 76 76 76 76 76 76 76 76 376 376 3</td> <td>9.1% 57.4% 14.9% 100.0% 14.9% 14.9% 14.9% 14.9% 14.9% 14.9% 14.9% 14.9% 14.9% 14.9% 14.9% 14.9% 10.6% 55; P = 5 14.4% 100.0% 55; P = 5</td> <td>i         2.0           i         1.1           i         1.1           i         1.1           i         1.1           i         1.4           Ni         1.4           N         1.4           N         1.4           N         1.4           N         1.7.2           i         3.60           i         3.60           i         3.60           i         3.60           i         3.61           i         3.33%           Rit         1.4.4           i         0.1.5           i         0.2.5</td> <td>16 [0.91; 4.67] 15 (0.75, 17.65] 15 (1.06, 1.755] 15 (1.08, 1.95] 10 (1.08, 1.95] 10 (1.08, 1.95] 10 (1.08, 1.95] 10 (1.08, 1.95) 10 (1.08, 1.95) 11 (1.04, 1.34) 15 (1.04, 1.34) 16 (1.04, 1.34) 17 (1.04, 1.34) 17 (1.04, 1.34) 18 (</td> <td>0.01</td> <td>Favours TURP Favours no-TURP Risk Ratio M.H. Fixed, 95% CI 0.1 10 100 Favours TURP Favours no-TURP Risk Ratio M.H. Random, 95% CI 0.1 10 50 Favours TURP Favours no-TURP Risk Ratio</td>	3         54           3         14           103         14           103         103           e0.24); P         100           non-TU         100           1         20           2         2           3         2           3         3           2         2           5         5           5         5           5         5           5         5           5         5           5         5           5         5           5         5           5         5           5         5           5         5           6         5           10         1	736 76 76 76 76 76 76 76 76 76 376 376 3	9.1% 57.4% 14.9% 100.0% 14.9% 14.9% 14.9% 14.9% 14.9% 14.9% 14.9% 14.9% 14.9% 14.9% 14.9% 14.9% 10.6% 55; P = 5 14.4% 100.0% 55; P = 5	i         2.0           i         1.1           i         1.1           i         1.1           i         1.1           i         1.4           Ni         1.4           N         1.4           N         1.4           N         1.4           N         1.7.2           i         3.60           i         3.60           i         3.60           i         3.60           i         3.61           i         3.33%           Rit         1.4.4           i         0.1.5           i         0.2.5	16 [0.91; 4.67] 15 (0.75, 17.65] 15 (1.06, 1.755] 15 (1.08, 1.95] 10 (1.08, 1.95] 10 (1.08, 1.95] 10 (1.08, 1.95] 10 (1.08, 1.95) 10 (1.08, 1.95) 11 (1.04, 1.34) 15 (1.04, 1.34) 16 (1.04, 1.34) 17 (1.04, 1.34) 17 (1.04, 1.34) 18 (	0.01	Favours TURP Favours no-TURP Risk Ratio M.H. Fixed, 95% CI 0.1 10 100 Favours TURP Favours no-TURP Risk Ratio M.H. Random, 95% CI 0.1 10 50 Favours TURP Favours no-TURP Risk Ratio
2015 Tugʻu 2021 Bannurah 2022 Garg Total (95% CI) Total events Heterogenelly: Chi <sup>3</sup> Test for overall effec F. marjor comp Study or Subgroup 2012 Zugor 2014 Hung 2015 Tugʻu 2022 Garg Total (95% CI) Total events Heterogenelly: Chi <sup>3</sup> Test for overall effec G. bladder nec Study or Subgroup 2015 Gellnaus 2015 Gellnaus 2015 Gellnaus 2015 Gellaus Total (95% CI) Total effect H. nerves spare Study or Subgroup 2010 Abedali 2010 Subgroup 2010 Abedali 2010 Zugor 2010 Abedali 2010 Zugor 2010 Abedali 2010 Zugor	111 313 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	3         3           3         3           3         3           3         5           3         7           3         7           8         7           8         7           9         7           10         8           11         5           27         18           80         16           11         12           27         18           80         16           11         12           27         18           80         16           11         12           27         18           80         16           11         12           215         3           215         3           217         18           30         215           37         37           37         37           37         37           37         37           37         37           37         37           37         37           37         37 <td>3         54           3         14           103         14           103         103           e0.24); P         100           non-TU         100           1         20           2         2           3         2           3         3           2         2           5         5           5         5           5         5           5         5           5         5           5         5           5         5           5         5           5         5           5         5           5         5           6         5           10         1</td> <td>736 76 76 76 76 76 76 80 80 184 36 76 376 376 376 376 376 376 376 376 3</td> <td>9.1% 57.4% 14.9% 100.0% 37.8% 6.0% 37.8% 6.0% 37.8% 6.0% 37.8% 100.0% 110.6% 8.2%.7% 8.2%.7% 8.2%.7% 100.0% 11.8% 4.0.0% 5); P=5 <b>Weighth</b> 11.9%</td> <td>i         2.0           i         1.1           i         1.1           i         1.1           i         1.1           i         1.4           Ni         1.4           N         1.4           N         1.4           N         1.4           N         1.7.2           i         3.60           i         3.60           i         3.60           i         3.60           i         3.61           i         3.33%           Rit         1.4.4           i         0.1.5           i         0.2.5</td> <td>In [0.91, 4.67] 5 [0.75, 1.76] 5 [0.75, 1.76] 5 [1.08, 1.95] 5 [1.08, 1.95] 5 [1.08, 1.95] 5 [1.08, 1.95] 5 [1.08, 1.95] 10 [0.3, 10.61] 10 [0.3, 10.61] 10 [0.3, 10.61] 10 [0.3, 10.61] 10 [0.5, 17.20] 7 [1.15, 1.169] 8 Ratio 8 Ratio 10 [0.5, 17.20] 10 [0.5, 17.</td> <td>0.01</td> <td>Favours TURP Favours no-TURP Risk Ratio M.H. Fixed, 95% CI 0.1 10 100 Favours TURP Favours no-TURP Risk Ratio M.H. Random, 95% CI 0.1 10 50 Favours TURP Favours no-TURP Risk Ratio</td>	3         54           3         14           103         14           103         103           e0.24); P         100           non-TU         100           1         20           2         2           3         2           3         3           2         2           5         5           5         5           5         5           5         5           5         5           5         5           5         5           5         5           5         5           5         5           5         5           6         5           10         1	736 76 76 76 76 76 76 80 80 184 36 76 376 376 376 376 376 376 376 376 3	9.1% 57.4% 14.9% 100.0% 37.8% 6.0% 37.8% 6.0% 37.8% 6.0% 37.8% 100.0% 110.6% 8.2%.7% 8.2%.7% 8.2%.7% 100.0% 11.8% 4.0.0% 5); P=5 <b>Weighth</b> 11.9%	i         2.0           i         1.1           i         1.1           i         1.1           i         1.1           i         1.4           Ni         1.4           N         1.4           N         1.4           N         1.4           N         1.7.2           i         3.60           i         3.60           i         3.60           i         3.60           i         3.61           i         3.33%           Rit         1.4.4           i         0.1.5           i         0.2.5	In [0.91, 4.67] 5 [0.75, 1.76] 5 [0.75, 1.76] 5 [1.08, 1.95] 5 [1.08, 1.95] 5 [1.08, 1.95] 5 [1.08, 1.95] 5 [1.08, 1.95] 10 [0.3, 10.61] 10 [0.3, 10.61] 10 [0.3, 10.61] 10 [0.3, 10.61] 10 [0.5, 17.20] 7 [1.15, 1.169] 8 Ratio 8 Ratio 10 [0.5, 17.20] 10 [0.5, 17.	0.01	Favours TURP Favours no-TURP Risk Ratio M.H. Fixed, 95% CI 0.1 10 100 Favours TURP Favours no-TURP Risk Ratio M.H. Random, 95% CI 0.1 10 50 Favours TURP Favours no-TURP Risk Ratio
2015 Tugću 2021 Bannurah 2022 Garg Total (95% CI) Total events Heterogenelly: Chi <sup>3</sup> Test for overall effec <b>F. marjor comp</b> Study or Subgroup 2012 Zugor 2014 Hung 2015 Tugću 2022 Garg Total (95% CI) Total events Heterogenelly: Chi <sup>3</sup> Test for overall effec <b>G. bladder nec</b> Study or Subgroup 2015 Gellnaus 2015 Gellnaus 2015 Gellnaus 2015 Subgroup Total (95% CI) Total events Heterogenelly: Tau <sup>3</sup> Test for overall effec <b>H. nerves spare</b> Study or Subgroup 2010 Abedali 2012 Zugor 2010 Subgroup 2010 Subgroup 2010 Subgroup 2010 Subgroup 2010 Subgroup 2015 Gellnaus 2015 Gellnaus 2015 Gellnaus 2015 Gellnaus	111 111 111 111 111 111 111 111	3         3           3         3           3         3           3         5           3         7           3         7           8         7           8         7           9         7           10         8           11         5           27         18           80         16           11         12           27         18           80         16           11         12           27         18           80         16           11         12           27         18           80         16           11         12           215         3           215         3           217         18           30         215           37         37           37         37           37         37           37         37           37         37           37         37           37         37           37         37 <td>3 5 4 3 14 103 102 102 102 102 102 102 102 102</td> <td>736 76 76 76 76 76 80 80 184 36 76 376 = 19% 80 184 27 132 80 80 76 76 76 76 76 76 77 80 76 76 77 80 76 80 184 22 36</td> <td>9.1% 57.4% 14.9% 100.0% 14.9% 14.9% 14.9% 14.9% 14.9% 14.9% 14.9% 14.9% 14.9% 14.9% 14.9% 14.9% 10.6% 55; P = 5 14.4% 100.0% 55; P = 5</td> <td>i         2.0.           i         1.1           i         1.1           i         1.1           i         1.1           i         1.4           r         MH           i         1.4           i         1.4           r         MH           i         1.7.2           i         3.60           i         3.60           i         3.60           i         3.60           i         3.60           i         3.60           i         3.61           i         0.71           i         0.41           i         0.75           i         0.75           i         0.75</td> <td>16 [0.91; 4.67] 15 (0.75, 17.65] 15 (1.06, 1.755] 15 (1.08, 1.95] 10 (1.08, 1.95] 10 (1.08, 1.95] 10 (1.08, 1.95] 10 (1.08, 1.95) 10 (1.08, 1.95) 11 (1.04, 1.34) 15 (1.04, 1.34) 16 (1.04, 1.34) 17 (1.04, 1.34) 17 (1.04, 1.34) 18 (</td> <td>0.01</td> <td>Favours TURP Favours no-TURP Risk Ratio M.H. Fixed, 95% CI 0.1 10 100 Favours TURP Favours no-TURP Risk Ratio M.H. Random, 95% CI 0.1 50 Favours TURP Favours no-TURP Risk Ratio</td>	3 5 4 3 14 103 102 102 102 102 102 102 102 102	736 76 76 76 76 76 80 80 184 36 76 376 = 19% 80 184 27 132 80 80 76 76 76 76 76 76 77 80 76 76 77 80 76 80 184 22 36	9.1% 57.4% 14.9% 100.0% 14.9% 14.9% 14.9% 14.9% 14.9% 14.9% 14.9% 14.9% 14.9% 14.9% 14.9% 14.9% 10.6% 55; P = 5 14.4% 100.0% 55; P = 5	i         2.0.           i         1.1           i         1.1           i         1.1           i         1.1           i         1.4           r         MH           i         1.4           i         1.4           r         MH           i         1.7.2           i         3.60           i         3.60           i         3.60           i         3.60           i         3.60           i         3.60           i         3.61           i         0.71           i         0.41           i         0.75           i         0.75           i         0.75	16 [0.91; 4.67] 15 (0.75, 17.65] 15 (1.06, 1.755] 15 (1.08, 1.95] 10 (1.08, 1.95] 10 (1.08, 1.95] 10 (1.08, 1.95] 10 (1.08, 1.95) 10 (1.08, 1.95) 11 (1.04, 1.34) 15 (1.04, 1.34) 16 (1.04, 1.34) 17 (1.04, 1.34) 17 (1.04, 1.34) 18 (	0.01	Favours TURP Favours no-TURP Risk Ratio M.H. Fixed, 95% CI 0.1 10 100 Favours TURP Favours no-TURP Risk Ratio M.H. Random, 95% CI 0.1 50 Favours TURP Favours no-TURP Risk Ratio
2015 Tugcu 2021 Bannurah 2022 Garg	111 311 112 112 112 112 112 112	36         36           37         36           38         37           38         55           39         38           39         38           39         38           30         38           30         38           50         37           30         38           50         57           30         38           50         57           30         38           50         57           50         57           50         57           50         57           50         57           50         57           50         57           50         57           50         57           50         57           50         57           50         57           50         57           50         57           50         57           50         57           50         57	3 5 4 3 14 103 102 102 102 102 102 102 102 102	736 76 76 76 76 76 80 80 184 36 76 376 80 80 80 80 80 80 80 80 80 80 80 80 80	9.1% 57.4% 57.4% 100.0% 100.0% 37.8% 37.8% 31.0% 25.2% 100.0% Weinht 12.9% 25.2% 100.0% 55; F = 5 10.4% 55; F = 5	i         2.0.           i         1.1           i         1.1           i         1.1           i         1.1           i         1.4           r         MH           i         1.4           i         1.4           r         MH           i         1.7.2           i         3.60           i         3.60           i         3.60           i         3.60           i         3.60           i         3.60           i         3.61           i         0.71           i         0.41           i         0.75           i         0.75           i         0.75	sk Ratio Fixed, 95% C1 (1), 10, 21, 10	0.01	Favours TURP Favours no-TURP Risk Ratio M.H. Fixed, 95% CI 0.1 10 100 Favours TURP Favours no-TURP Risk Ratio M.H. Random, 95% CI 0.1 50 Favours TURP Favours no-TURP Risk Ratio

#### **Functional outcomes**

Given the importance of long-term urinary and sexual function, only the data of incontinence or potency at 1 year were extracted for analysis. At 1-year follow-up, 16.4% patients in TURP group remained incontinence which was significantly higher than that in no-TURP group (9.6%) (RR: 1.54, 95% CI: 1.19–2, P < 0.001, Table 2 and Fig. 3). In addition, patients in the TURP group also reported lower sexual satisfaction (potency at 1 year: 49.4% vs. 59.1%, RR: 0.8, 95% CI: 0.73–0.89, P < 0.001, Table 2 and Fig. 3).

### **Oncologic outcomes**

All ten articles reported positive margins, the pooled outcomes indicated a higher rate positive margin in TURP group compared with no-TURP group (RR: 1.24, 95% CI: 1.02–1.52, P = 0.03, Table 2 and Fig. 3). Only three articles [3, 4, 16] reported BCR at 1 year and one article [8] reported BCR at last follow-up, thus data of BCRs at 1 year were extracted for pooled analysis. There were no statistical differences in BCR at 1 year between groups (RR: 1.41, 95% CI: 0.87–2.29, P = 0.16, Table 2 and Fig. 3).

## **Publication bias**

There was no discernible asymmetry in the Begg's funnel plot of the results (Supplemental Fig. 1). Moreover, Egger's test P values for each outcome were > 0.05, also indicating no substantial publication bias.

## Discussion

Incidental cancer of the prostate is found in 3–16% of specimens from TURP [17] and these patients are recommended to receive radical prostatectomy after 3 months. The question of whether a previous TURP has an adverse impact on a future RARP stays debatable at now. To further elucidate these topics, we conducted a meta-analysis and systematic review of the relevant literature.

There are several concerns with respect to the post TURP scenario: (1) potential causes of periprostatic inflammation and fibrosis include infection of the prostate, capsular rupture, and extravasation of irrigation fluid after a TURP [18], (2) inflammation-induced increases in periprostatic adhesions following TURP recovery [19], (3) once the prostate is removed, the prostatovesical junction becomes lax and difficult to define [3], (4) an improper urethrovesical anastomosis is impeded by the surrounding fibrosis, which makes it difficult to identify and preserve appropriate residual urethral length [3], (5) identifying NVBs can be challenging because to periprostatic adhesions, which can make NVB

sparing problematic, (6) when a TURP is performed, the ureteric orifices are pulled closer to the bladder neck, making it more difficult to distinguish between the two [19]. Collectively, these factors may exacerbate the difficulties of RARP following TURP, which is consistent with our findings. Consistent with this, the pooled results of our meta-analysis revealed that TURP group had worse surgical outcomes int terms of longer operative time, more blood loss, longer time to catheter removal, higher rates of overall and major complications, frequently demand for bladder neck reconstruction and lower succeed in nerve sparing.

Maintaining the quality of life is an important secondary goal after radical prostatectomy. Urinary incontinence and sexual dysfunction are the most frequent and distressing factors affecting the quality of life for men after radical prostatectomy. The cause of urinary incontinence after radical prostatectomy remains unknown. Pre-prostatectomy physical activity and obesity are important factors in post-prostatectomy continence levels [20]. Besides, surgical technique and surgeon experience are associated with postoperative urinary incontinence [21, 22]. Our results indicated prior TURP also had malign effect on subsequent RARP regarding to long-term incontinence. According to literature reports, selective deep dorsal vein complex division, puboprostaticsparing techniques, nerve-sparing technique, and restoration of the pelvis space as well as anterior and posterior musculofascial reconstruction were advocated as surgical aspects potentially able to lessen the likelihood of urinary incontinence after RARP [23, 24]. In addition, recovery of continence is enhanced in the short-, intermediate-, and longterm with pelvic floor muscle training administered both pre- and post-operatively [25]. Taken together, patients who have undergone RARP, particularly those who have undergone prior TURP, benefit from a mix of surgical methods and rehabilitation in order to regain continence. Despite the fact that radical prostatectomy is primarily performed on the elderly, still many patients are concerned about their sexual function recovery. Almost half patients remain impotency at 1 year in TURP group, which is more prevalent than no-TURP Group. Both urologists and patients should be aware of this important information.

The presence of a positive margin adversely affects biochemical recurrence and cause specific survival in men with Pca [26]. In our study, positive margins were found to be significantly greater in TURP group compared with the no-TURP group. However, higher positive margins did not increase the biochemical recurrence rate at 1 year in our results. Actually, the rate of biochemical recurrence in each extracted studies [3, 4, 4, 16] is higher in TURP group than that in no-TURP group, despite statistically insignificant. Considering the paucity number of included patients and the relatively low incidence of short-term biochemical recurrence, it is plausible to suppose that RARP following TURP

## A. incontinence at 1 year

	TURP			TURP no-TURP		Risk Ratio		Risk	Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl		M-H, Fixe	d, 95% Cl	
2011Gupta	2	8	7	85	1.6%	3.04 [0.75, 12.24]				$\rightarrow$
2012 Zugor	10	80	7	80	9.4%	1.43 [0.57, 3.57]			•	
2014 Hung	1	16	4	184	0.9%	2.88 [0.34, 24.22]				$\rightarrow$
2015 Tugcu	3	25	7	36	7.7%	0.62 [0.18, 2.16]	←			
2021 Bannurah	66	368	88	736	78.7%	1.50 [1.12, 2.01]				
2022 Garg	6	38	2	76	1.8%	6.00 [1.27, 28.33]				$\rightarrow$
Total (95% CI)		535		1197	100.0%	1.54 [1.19, 2.00]			•	
Total events	88		115							
Heterogeneity: Chi <sup>2</sup> =	6.29, df=	5 (P =	0.28); I <sup>2</sup> =	= 21%			0.2	0.5 1		-
Test for overall effect:	Z = 3.28	(P = 0.0	001)				0.2		Favours no-TURP	5

## B. potency at 1year

	TUR	Р	no-TURP Risk Ratio			Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M-H, Fixed, 95% Cl
2011Gupta	1	5	20	61	0.8%	0.61 [0.10, 3.65]	
2012 Zugor	38	80	58	80	14.9%	0.66 [0.50, 0.86]	
2015 Tugcu	12	25	22	36	4.6%	0.79 [0.48, 1.27]	
2021 Bannurah	191	368	464	736	79.3%	0.82 [0.74, 0.92]	
2022 Garg	3	18	3	46	0.4%	2.56 [0.57, 11.51]	
Total (95% CI)		496		959	100.0%	0.80 [0.73, 0.89]	•
Total events	245		567				
Heterogeneity: Chi <sup>2</sup> =	Heterogeneity: Chi <sup>2</sup> = 4.79, df = 4 (P = 0.31); I <sup>2</sup> = 16%						
Test for overall effect:	Z= 4.26	(P < 0.0	Favours no-TURP Favours TURP				

## C. positive margin

	TURP		no-TURP		Risk Ratio		Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M-H, Fixed, 95% Cl
2008 Hampton	18	51	18	102	9.3%	2.00 [1.14, 3.50]	
2010 Abedali	6	27	5	27	3.9%	1.20 [0.42, 3.46]	
2011Gupta	4	18	17	132	3.2%	1.73 [0.65, 4.56]	
2012 Zugor	6	80	4	80	3.1%	1.50 [0.44, 5.11]	
2014 Hung	7	16	74	184	9.2%	1.09 [0.61, 1.95]	
2015 Gellhaus	2	11	3	22	1.6%	1.33 [0.26, 6.85]	
2015 Tugcu	3	25	4	36	2.6%	1.08 [0.26, 4.41]	
2015Su	15	49	554	2644	15.7%	1.46 [0.95, 2.24]	<b></b>
2021 Bannurah	45	368	88	736	45.7%	1.02 [0.73, 1.43]	
2022 Garg	6	38	11	76	5.7%	1.09 [0.44, 2.72]	
Total (95% CI)		683		4039	100.0%	1.24 [1.02, 1.52]	◆
Total events	112		778				
Heterogeneity: Chi <sup>2</sup> =	5.46, df=	9 (P =	0.79); I <sup>2</sup> :	= 0%			
Test for overall effect:					0.05 0.2 1 5 20 Favours TURP Favours no-TURP		

# D. biochemical recurrence-free rates at 1 year

	TUR	Р	no-TURP Risk Ratio				Risk				
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl		M-H, Fix	ed, 95% Cl		
2011Gupta	3	8	9	85	6.8%	3.54 [1.19, 10.50]					
2014 Hung	3	16	21	184	14.7%	1.64 [0.55, 4.92]		_	<b></b> -		
2021 Bannurah	16	368	27	736	78.6%	1.19 [0.65, 2.17]		-			
Total (95% CI)		392		1005	100.0%	1.41 [0.87, 2.29]			•		
Total events	22		57								
Heterogeneity: Chi <sup>2</sup> =	Heterogeneity: Chi <sup>2</sup> = 3.14, df = 2 (P = 0.21); I <sup>2</sup> = 36%								1	10	100
Test for overall effect: Z = 1.40 (P = 0.16)								0.1 Favours TURP	Favours		

Fig. 3 Forest plot of incontinence at 1 year (A), potency at 1 year (B), positive margin (C), biochemical recurrence-free rates at 1 year (D)

offers worse long-term oncologic outcomes. Nevertheless, future research using well-designed, large samples and extensive follow-up is needed to corroborate these findings.

Considering prior TURP compromises surgical, functional and oncological outcomes of subsequent RARP, any attempt to prevent the incidentally discovery of Pca by TURP should be accomplished. PSA screening is routinely recommend for men aged older than 50 years and is associated with an increased early detection of PCa [27]. However, foley catheterization [28] and larger prostate volume in BPH patients are associated with elevated PSA level, which may confused the urologists. Patients with BPH who are at risk of Pca should have a digital rectal exam [27]. Meanwhile, multiparametric magnetic resonance imaging undoubtedly facilitates the detection of clinical Pca [29]. Combining the PI-RADS score with the PSAD, as described in the published work by Wang et al. [30], has been shown to increase diagnostic certainty for prostate cancer and decrease the number of needless prostate biopsies. Furthermore, PSMA PET/CT can discriminate clinically significant prostate cancer from benign prostate diseases in patients with suspected prostate cancer [31]. Taken together, detailed assessment for elderly individuals with BPH can help them avoid unneeded TURP surgery.

There are some limitations that had to be taken into account. First, all included studies were retrospective. Improper randomization and lack of blinding were major sources of bias. Nevertheless, benefits of patients and ethical considerations prevent a randomized controlled trial from being conducted. Second, differences in surgical equipment and techniques between TURP and RARP might have an impact on the outcomes. Third, there was identified variability in a number of continuous variables. Consequently, the random-effects model was used to lessen the influence of heterogeneity, although it was unable to eradicate it entirely. Fourth, possibly due to its non-normal distribution properties, continuous variables were sometimes given as median and range in research. Statistical techniques were used in our calculations of the mean and standard deviation, which may introduce some degree of error.

In conclusion, RARP is feasible but challenging after TURP. It significantly increases the difficulty of operation and compromises surgical, functional and oncological outcomes. It is important for urologists and patients to be aware of the negative impact of TURP on subsequent RARP and establish treatment strategies perioperatively and post-operatively to lessen the adverse effects.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s11701-023-01588-w.

Author contributions LG: statistical analysis, data extraction, revised manuscripts. YL: statistical analysis, data extraction. XL: statistical analysis, data extraction. WL: study design, statistical analysis, data

extraction, wrote the paper. All the authors contributed to the article and approved the submitted version.

Funding The author have not disclosed any funding.

**Data availability** Data will be made available for bona fide researchers on request.

#### Declarations

**Conflict of interest** All the authors have no conflict of interest to declare. All the authors have no conflict of financial and non-financial interest to declare.

## References

- Siegel RL, Miller KD, Fuchs HE, Jemal A (2022) Cancer statistics, 2022. CA Cancer J Clin 72:7–33. https://doi.org/10.3322/ caac.21708
- Gray PJ, Lin CC, Cooperberg MR, Jemal A, Efstathiou JA (2017) Temporal trends and the impact of race, insurance, and socioeconomic status in the management of localized prostate cancer. Eur Urol 71:729–737. https://doi.org/10.1016/j.eururo.2016.08.047
- Gupta NP, Singh P, Nayyar R (2011) Outcomes of robot-assisted radical prostatectomy in men with previous transurethral resection of prostate. BJU Int 108:1501–1505. https://doi.org/10.1111/j. 1464-410X.2011.10113.x
- Hung CF, Yang CK, Ou YC (2014) Robotic assisted laparoscopic radical prostatectomy following transurethral resection of the prostate: perioperative, oncologic and functional outcomes. Prostate Int 2:82–89. https://doi.org/10.12954/PI.14046
- Su YK et al (2015) Does previous transurethral prostate surgery affect oncologic and continence outcomes after RARP? J Robot Surg 9:291–297. https://doi.org/10.1007/s11701-015-0529-9
- Garg H, Seth A, Kumar R (2022) Impact of previous transurethral resection of prostate on robot-assisted radical prostatectomy: a matched cohort analysis. J Robot Surg 16:1123–1131. https://doi. org/10.1007/s11701-021-01348-8
- Tugcu V et al (2015) Robot-assisted radical prostatectomy after previous prostate surgery. JSLS 19:e2015 00080. https://doi.org/ 10.4293/JSLS.2015.00080
- Gellhaus PT et al (2015) Robot-assisted radical prostatectomy in patients with a history of holmium laser enucleation of the prostate: feasibility and evaluation of initial outcomes. J Endourol 29:764–769. https://doi.org/10.1089/end.2014.0767
- Zugor V, Labanaris AP, Porres D, Witt JH (2012) Surgical, oncologic, and short-term functional outcomes in patients undergoing robot-assisted prostatectomy after previous transurethral resection of the prostate. J Endourol 26:515–519. https://doi.org/10.1089/ end.2011.0205
- Shamseer L et al (2015) Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 350:g7647. https://doi.org/10.1136/ bmj.g7647
- Wan X, Wang W, Liu J, Tong T (2014) Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol 14:135. https://doi.org/10.1186/1471-2288-14-135
- Downs SH, Black N (1998) The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Comm Health 52:377–384. https://doi.org/10.1136/ jech.52.6.377

- DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188. https://doi.org/10.1016/0197-2456(86)90046-2
- Hampton L, Nelson RA, Satterthwaite R, Wilson T, Crocitto L (2008) Patients with prior TURP undergoing robot-assisted laparoscopic radical prostatectomy have higher positive surgical margin rates. J Robot Surg 2:213–216. https://doi.org/10.1007/ s11701-008-0121-7
- Abedali ZA et al (2020) Robot-assisted radical prostatectomy in patients with a history of holmium laser enucleation of the prostate: the Indiana university experience. J Endourol 34:163–168. https://doi.org/10.1089/end.2019.0436
- Leyh-Bannurah SR et al (2021) Perioperative and postoperative outcomes of robot-assisted radical prostatectomy in prostate cancer patients with prior transurethral subvesical deobstruction: results of a high-volume center. J Urol 206:308–318. https://doi. org/10.1097/JU.000000000001776
- Merrill RM, Wiggins CL (2002) Incidental detection of population-based prostate cancer incidence rates through transurethral resection of the prostate. In: Urologic oncology: seminars and original investigations. Elsevier vol 7, no 5, pp 213–219
- Colombo R et al (2006) Radical prostatectomy after previous prostate surgery: clinical and functional outcomes. J Urol 176:2459– 2463. https://doi.org/10.1016/j.juro.2006.07.140
- Rassweiler J, Teber D, Kuntz R, Hofmann R (2006) Complications of transurethral resection of the prostate (TURP)–incidence, management, and prevention. Eur Urol 50:969–979. https://doi. org/10.1016/j.eururo.2005.12.042
- Wolin KY, Luly J, Sutcliffe S, Andriole GL, Kibel AS (2010) Risk of urinary incontinence following prostatectomy: the role of physical activity and obesity. J Urol 183:629–633
- 21. Sandhu JS et al (2019) Incontinence after prostate treatment: AUA/SUFU guideline. J Urol 202:369–378
- Cooperberg MR, Odisho AY, Carroll PR (2012) Outcomes for radical prostatectomy: is it the singer, the song, or both? J Clin Oncol Off J Am Soc Clin Oncol 30:476–478
- Checcucci E et al (2021) The importance of anatomical reconstruction for continence recovery after robot assisted radical prostatectomy: a systematic review and pooled analysis from referral centers. Minerva Urol Nephrol 73:165–177. https://doi.org/10. 23736/S2724-6051.20.04146-6

- Mungovan SF et al (2021) Preoperative exercise interventions to optimize continence outcomes following radical prostatectomy. Nat Rev Urol 18:259–281. https://doi.org/10.1038/ s41585-021-00445-5
- Fernandez RA et al (2015) Improvement of continence rate with pelvic floor muscle training post-prostatectomy: a meta-analysis of randomized controlled trials. Urol Int 94:125–132. https://doi. org/10.1159/000368618
- Yossepowitch O et al (2009) Positive surgical margins in radical prostatectomy: outlining the problem and its long-term consequences. Eur Urol 55:87–99. https://doi.org/10.1016/j.eururo. 2008.09.051
- Mottet N et al (2017) EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 71:618–629. https://doi.org/10.1016/j.eururo. 2016.08.003
- 28. Anand A, Gupta S (2021) Prostate-specific antigen increase after urethral catheterisation: fact or myth. Afr J Urol 27:1–3
- Johnson DC et al (2019) Detection of individual prostate cancer foci via multiparametric magnetic resonance imaging. Eur Urol 75:712–720. https://doi.org/10.1016/j.eururo.2018.11.031
- Wang C et al (2022) Combination of PI-RADS score and PSAD can improve the diagnostic accuracy of prostate cancer and reduce unnecessary prostate biopsies. Front Oncol 12:1024204. https:// doi.org/10.3389/fonc.2022.1024204
- 31. Jiao J et al (2021) Establishment and prospective validation of an SUV(max) cutoff value to discriminate clinically significant prostate cancer from benign prostate diseases in patients with suspected prostate cancer by (68)Ga-PSMA PET/CT: a real-world study. Theranostics 11:8396–8411. https://doi.org/10.7150/thno. 58140

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.